Navigation Links
Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty-Plus Year Historic Relationship
Date:7/30/2009

  • Providing a framework for identifying and cultivating joint opportunities for philanthropic development; and
  • Identifying approaches to co-brand select clinical programs.

    • Montefiore Medical Center encompasses 125 years of outstanding patient care, innovative medical "firsts," pioneering clinical research, dedicated community service and ground-breaking social activism. A full-service, integrated delivery system caring for patients in the New York metropolitan region and beyond, Montefiore is a 1,491-bed medical center that includes: four hospitals -- the Henry and Lucy Moses Division, the Jack D. Weiler Division, the North Division and The Children's Hospital at Montefiore; a large home healthcare agency; the largest school health program in the US; a 25-site medical group practice integrated throughout the Bronx and Westchester; and, a care management organization providing services to 179,000 health plan members.

    In 2008, The Children's Hospital at Montefiore was ranked as one of "America's Best Children's Hospitals" in US News & World Report's prestigious annual listing and also received honors in the magazine's 2009 edition. The Leapfrog Group lists Montefiore among the top one percent of all U.S. hospitals based on its strategic investments in sophisticated and integrated healthcare technology.

    Montefiore is committed to meeting the healthcare needs of the future through medical education and manages one of the largest residency programs in the country. Montefiore is The University Hospital and Academic Medical Center for

    SOURCE Montefiore Medical Center
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4

    Related medicine technology :

    1. Peripheral Arterial Disease to be Treated With New Medicated Stent in Trial at Montefiore
    2. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
    3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    4. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
    5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    6. Globus Medical Raises $110 Million in Series E Financing Round
    7. Quark Pharmaceuticals Appoints New Chief Medical Officer
    8. Boston University Biomedical Engineers Find Chink in Bacterias Armor
    9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
    10. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
    11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Catholics for Choice Statement on Healthcare Reform Bill 60931 1Catholics for Choice Statement on Healthcare Reform Bill 60931 2Findings show nanomedicine promising for treating spinal cord injuries 10653 1Findings show nanomedicine promising for treating spinal cord injuries 10653 2Findings show nanomedicine promising for treating spinal cord injuries 10653 3APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 60929 1APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 60929 2